Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-23-001959
Filing Date
2023-05-18
Accepted
2023-05-18 16:09:36
Documents
43
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zk2329747.htm   iXBRL 10-Q 574471
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 8209
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 8026
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 5318
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 5200
  Complete submission text file 0001178913-23-001959.txt   2832526

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE atms-20230331.xsd EX-101.SCH 34010
7 XBRL CALCULATION FILE atms-20230331_cal.xml EX-101.CAL 29285
8 XBRL DEFINITION FILE atms-20230331_def.xml EX-101.DEF 35835
9 XBRL LABEL FILE atms-20230331_lab.xml EX-101.LAB 430546
10 XBRL PRESENTATION FILE atms-20230331_pre.xml EX-101.PRE 139134
37 EXTRACTED XBRL INSTANCE DOCUMENT zk2329747_htm.xml XML 301762
Mailing Address 3 ELIEZER VARDINON ST. PETACH TIKVA L3 4959507
Business Address 3 ELIEZER VARDINON ST. PETACH TIKVA L3 4959507 646-233-1454
Artemis Therapeutics, Inc. (Filer) CIK: 0001062128 (see all company filings)

EIN.: 841417774 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24431 | Film No.: 23936137
SIC: 2890 Miscellaneous Chemical Products